scientific name for retatrutide Demand Unapproved Weight-Loss Drug Surges on Social Media what is retatrutide brand name

Compounded Tirzepatide Compounded Semaglutide Same active ingredient as Ozempic & Wegovy GLP-1 receptor agonist (single target) Average weight loss: ~15% of body weight Once-weekly subcutaneous injection Gradual dose titration over 48 weeks Well-studied safety profile Good starting option for most patients Compounded Tirzepatide Same active ingredient as Mounjaro & Zepbound Dual GLP-1 + GIP receptor agonist Average weight loss: up to 21% of body weight Once-weekly subcutaneous injection Gradual dose titration over 48 weeks Additional blood sugar regulation via GIP pathway May be more effective for patients with insulin resistance Not sure which is right for you

Mounjaro Savings Card covers up to $650 monthly for commercially insured patients, potentially reducing out-of-pocket costs to $25-100 monthly

N Engl J Med 2015;373:22472257

Is this safe

Key Figures at a Glance Eli Lilly Q1 2026: total revenue $19.8B (+56% YoY), adjusted EPS $8.55 (+156%), full-year guidance raised to $82-85B Mounjaro + Zepbound combined Q1 revenue: $12.8B, with Mounjaro at $8.66B and Zepbound at $4.16B Foundayo (orforglipron): FDA approved April 1, 2026

J Hepatol (2016) 64:1388402